Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer

Ajouter une nouvelle offre d'emploi Health

2025-04-10 11:23:16 -

The lung cancer therapeutics market has been significantly reshaped by the discovery and targeting of rare biomarkers for non-small cell lung cancer (NSCLC), particularly MET exon 14 skipping alterations. These rare genomic alterations have led to the development of targeted therapies, dramatically improving patient outcomes and transforming the lung cancer biomarker market. Until...

0 Commentaires 0 Parts 305 Vue 0 Aperçu